Theriva Biologics’ experimental treatment VCN-01 safely increased survival when used in addition to chemotherapy for people with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC),…
Pancreatic cancer
PANCREATIC CANCER
FDA OKs clinical testing of oral treatment for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has given Verastem Oncology the green light to start clinical testing of its oral treatment candidate VS-7375…
PANCREATIC CANCER
MUC5AC protein could predict pancreatic cancer prognosis: Study
Blood levels of the MUC5AC protein could help predict outcomes in people who have surgery for pancreatic ductal adenocarcinoma (PDA), the most common type of…
PANCREATIC CANCER
Drug combo may be effective as treatment for pancreatic cancer
A combination of drugs to block two proteins, called PRMT5 and Chk1, may be effective for the treatment of pancreatic cancer, according to new…
PANCREATIC CANCER
Immunotherapy implant promising for treating pancreatic cancers
A new approach in immunotherapy that can safely boost the body’s immune response has shown promise in hard-to-treat tumors like pancreatic cancers, a study…
PANCREATIC CANCER
Blocking FGFR2 may stop pancreatic cancer from developing
Blocking the activity of a protein called FGFR2 may prevent some pancreatic cancers from developing, a study in mice indicated. The study, “…
PANCREATIC CANCER
Cabometyx wins FDA approval for treating certain pancreatic cancers
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
PANCREATIC CANCER
FDA grants orphan drug status to PEP-010 for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Pep-Therapy‘s PEP-010, a potential first-in-class treatment for pancreatic cancer. The…
PANCREATIC CANCER
OSE2101 vaccine shows ‘promising benefit’ in pancreatic cancer trial
Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in a Phase 2 clinical trial…
PANCREATIC CANCER
SIL204 reduces tumors, slows spread in pancreatic cancer models
Administering Silexion Therapeutics‘ investigational therapy SIL204 under the skin effectively reduced the growth of primary tumors and their metastatic spread to various organs in…
Recent Posts
- Phase 3 trial testing if oral pill can stop pancreatic cancer from returning
- Vyriad targets 2026 clinical trial for new experimental cell therapy VV169
- Olverembatinib and chemo show deep response in trial for Ph-positive ALL
- Pancreatic cancer treatment atebimetinib set for Phase 3 trial
- 1st trial participant receives Alpha DaRT radiation therapy for glioblastoma
